SynthesisEBioMedicine2017
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.
Synthesis in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis.Systematic reviews · 2018Pooled it
- Alzheimer's disease target and drug discovery by leveraging multiomics and electronic health data.Nature neuroscience · 2026Article
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.Clinical pharmacology and therapeutics · 2026Article
- Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data.Clinical and translational science · 2026Review
- Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management.Endocrinology, diabetes & metabolism · 2026Review
- Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.Frontiers in pharmacology · 2026Article
- Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.American journal of translational research · 2026Review
- A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report.Cancer management and research · 2026Article
- Investigation of Pharmacogenomic Variants in the CYP (P450) Family in Native American Populations of the Brazilian Amazon.International journal of genomics · 2026Article
- Comparing self-reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models.Molecular oncology · 2025Article
- Review
- Clinical Trial Safety Surveillance in Africa: Experts' Perspectives on Current Practices and Opportunities.Vaccines · 2025Article
- Building Sub-Saharan African PBPK Populations Reveals Critical Data Gaps: A Case Study on Aflatoxin B1.Toxins · 2025Article
- Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Appraising the visibility, relevance and impacts of clinical pharmacology.British journal of clinical pharmacology · 2025Review
- Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review.Cureus · 2025Review
- A new dawn: Vitalising translational oncology research in Africa with the help of advanced cell culture models.Translational oncology · 2025Article
- Stepping Up Medicinal Chemistry Capabilities in Sub-Saharan Africa: Perspectives from Early Career African Drug Discovery Researchers.Journal of medicinal chemistry · 2025Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic diversity is greater in Africa than in other continental populations. Genetic variability in genes encoding drug metabolizing enzymes may contribute to the high numbers of adverse drug reactions reported in Africa. We reviewed publications (1995-April 2016) reporting frequencies of known cytochrome P450 (CYP) variants in African populations. Using principal components analysis (PCA) we identified CYP alleles of potential clinical relevance with a marked difference in distribution in Africa, compared with Asian and Caucasian populations. These were CYP2B6*6, CYP2C8*2, CYP2D6*3, CYP2D6*17, CYP2D6*29, CYP3A5*6, and CYP3A5*7. We show clearly that there is greater diversity in CYP distribution in Africa than in other continental populations and identify a need for optimization of drug therapy and drug development there. Further pharmacogenetic studies are required to confirm the CYP distributions we identified using PCA, to discover uniquely African alleles and to identify populations at a potentially increased risk of drug-induced adverse events or drug inefficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.